JP2020515286A5 - - Google Patents

Download PDF

Info

Publication number
JP2020515286A5
JP2020515286A5 JP2019567512A JP2019567512A JP2020515286A5 JP 2020515286 A5 JP2020515286 A5 JP 2020515286A5 JP 2019567512 A JP2019567512 A JP 2019567512A JP 2019567512 A JP2019567512 A JP 2019567512A JP 2020515286 A5 JP2020515286 A5 JP 2020515286A5
Authority
JP
Japan
Prior art keywords
antibody
seq
cancer
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019567512A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515286A (ja
JP7325045B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/020050 external-priority patent/WO2018157169A1/en
Publication of JP2020515286A publication Critical patent/JP2020515286A/ja
Publication of JP2020515286A5 publication Critical patent/JP2020515286A5/ja
Application granted granted Critical
Publication of JP7325045B2 publication Critical patent/JP7325045B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019567512A 2017-02-27 2018-02-27 癌を処置する抗体コンストラクトおよび方法 Active JP7325045B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762463868P 2017-02-27 2017-02-27
US62/463,868 2017-02-27
PCT/US2018/020050 WO2018157169A1 (en) 2017-02-27 2018-02-27 Antibody constructs and methods of treating cancer

Publications (3)

Publication Number Publication Date
JP2020515286A JP2020515286A (ja) 2020-05-28
JP2020515286A5 true JP2020515286A5 (enExample) 2022-01-04
JP7325045B2 JP7325045B2 (ja) 2023-08-14

Family

ID=63254387

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019567512A Active JP7325045B2 (ja) 2017-02-27 2018-02-27 癌を処置する抗体コンストラクトおよび方法

Country Status (6)

Country Link
US (1) US11623953B2 (enExample)
EP (1) EP3585819A4 (enExample)
JP (1) JP7325045B2 (enExample)
CN (1) CN111148760A (enExample)
CA (1) CA3092434A1 (enExample)
WO (1) WO2018157169A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023013637A (es) * 2021-05-19 2024-02-13 Prec Biologics Inc Metodos y composiciones para tratar neoplasias hematicas.
WO2024091848A2 (en) * 2022-10-25 2024-05-02 The Trustees Of The University Of Pennsylvania Anti-ceacam6 car-t cells for the treatment of ceacam6+ tumors
WO2025006562A1 (en) * 2023-06-27 2025-01-02 Bio4T2, Llc Methods of car administration and treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
JP4287147B2 (ja) * 2000-11-02 2009-07-01 イミュノセルラー・セラピューティクス・リミテッド 小細胞肺癌(sclc)の検出および治療のためのモノクローナル抗体および細胞表面抗原
JP4694128B2 (ja) 2002-01-30 2011-06-08 ザ ブライハム アンド ウイメンズ ホスピタル, インコーポレイテッド TIM−3、Th1特異的細胞表面分子に関連した組成物および方法
JP2008500013A (ja) 2003-10-03 2008-01-10 ザ ブライハム アンド ウイメンズ ホスピタル,インコーポレイテッド Tim−3ポリペプチド
PL1866414T3 (pl) 2005-03-31 2012-10-31 Calando Pharmaceuticals Inc Inhibitory podjednostki 2 reduktazy rybonukleotydowej i ich zastosowania
CN101607985B (zh) 2008-12-24 2013-03-27 中国科学院生物物理研究所 抗人cea的单克隆抗体,包含其的组合物,及其用途
ES2664989T3 (es) * 2010-10-01 2018-04-24 National Research Council Of Canada Anticuerpos ANTI-CEACAM6 y usos de los mismos
CN103421113B (zh) * 2012-05-22 2018-01-19 武汉华鑫康源生物医药有限公司 抗BLyS抗体
US10647768B2 (en) * 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
JP6815329B2 (ja) * 2015-03-23 2021-01-20 バイエル ファーマ アクチエンゲゼルシャフト 抗ceacam6抗体およびその使用

Similar Documents

Publication Publication Date Title
CN112574307B (zh) 抗人Claudin18.2抗体及其应用
JP2024522360A5 (enExample)
JP7209464B2 (ja) ヒトインターロイキン-2に対する免疫刺激性モノクローナル抗体
JP2020534830A5 (enExample)
JP6239503B2 (ja) 新規な抗cxcr4抗体並びに癌の検出および診断のためのその使用
RU2018124602A (ru) Новые анти-pd-l1 антитела
AU2011278562C1 (en) Novel antibody for the diagnosis and/or prognosis of cancer
JP2021516051A5 (enExample)
JP2019527553A5 (enExample)
JP2021500916A5 (enExample)
KR102661060B1 (ko) 항인간 IgG4 모노클로날 항체, 및 그 항체를 이용한 인간 IgG4 측정 시약
KR20130012132A (ko) 암의 치료를 위한 인간화 항-cxcr4 항체들
JP2017538439A5 (enExample)
CN113227148B (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
CN112094348B (zh) 抗人Tim3抗体或其功能性片段及其应用
WO2022074648A1 (en) Marker for response to pd-1/pd-l1 immunotherapy
JP2021525719A5 (enExample)
US20190194319A1 (en) Anti-ascl1 antibodies and methods of use
KR102350259B1 (ko) Igf-1r 항체 및 암의 진단을 위한 그의 용도
CN105683755B (zh) 陷阱分子和检测分子的用途及其相关试剂盒和组合物
CN116003615A (zh) 一种抗卡利普多的单克隆抗体及其应用
CN116836291B (zh) 抗cd47-cldn18.2双特异性抗体的抗独特型抗体及其制备方法和应用
TWI869740B (zh) 一種體外檢測sTNFR2蛋白濃度的方法及其檢測試劑和檢測試劑盒
WO2018213680A1 (en) Diagnostic antibodies and methods of use
JP6407990B2 (ja) アウグリン免疫学的検定